Last month at the "den" there was a major concern about
Last month at the "den" there was a major concern about board members receiving 100k in shares. This particular poster stated that if this trend continues thats 9m shares at 0.0 and a 2150% increase in shares given to the Board of Directors. Well I saw no commentary last night regarding this statement as the "poster" had the ability to actually admit we were not going to see 9m shares at 0.0. and a 2150% increase in shares. YESTERDAY AFTERNOON THE BOD'S WERE GIVEN 4K SHARES FOR ATTENDING THEIR MEETING. THE SENSATIONALISM USED TO TALK IN THE STOCK DIDN'T WORK AGAIN AS CLEARLY THIS POSTER IS NOT LONG OR IF HIS IS VERY NOMINAL.
Look at the trend from this poster. Mid December he pulled out the "boogeyman" attempt from 12/15 to 12/19. Why because during 2014 on 4 to 5 seperate occasions scrc could not break .14. LOOK AT THE TIMING OF THE BOOGEYMAN SCRC WAS SITTING AT .14. IS THAT A COINCIDENCE THAT FOR THE 1ST TIME IN 2 YEARS THIS "POSTER" PULLS OUT THE "BOOGEYMAN" EXACTLY AT .14 WHERE IT WAS A VERY ROUGH SPOT FOR SCRC TO GET THRU.
My Observation most longs would feel pretty good about scrc being .20 to .21 this particular "poster" does he seem europhric to you????? I mean after all dec 12th we sat at .1097 and now we sit at .20 6 to 7 weeks later and does he seem happy or happier than most????????? All I hear is things like if scrc does x amount in january it will kill the sp. If scrc matches q4 of 2014 with a same # in q1 2015 it will kill the sp.
Regarding the "poster's" price to sell since when did he know everyone's parameter to sell?????? How does he know people's price to sell is 40% higher????? Actually isn't this the same "poster" who said be nimble and vigilant??????? is a 40% price to sell considered nimble and vigilant??????? What this poster does he in effect puts on a straddle so he can hedge all the plethoria of rhetoric that comes out of his mouth.
Bottom Line: As Guts stated the higher SCRC goes he will be gone and massive crew that he has working our running out of stories. The fundamentals are what counts here. We can now put to rest the 9m shares theory as well as the 2150% surge in shares to bod.
ScripsAmerica Inc (SCRC) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Aiming for the Photography Crown ON1 isn't just tinkering on the fringes with their new Photo RAW 2027 release—they're diving headfirst into the deep end, aiming to outdo giants in the RAW processing world. I've seen my share of software updates that don't move the needle, but this one's packed to the gills with updates that photographers have been clamoring for. What's...
Continue Reading
The Bold Shift in China's Economic Landscape Well, here's the scoop: China isn't just the world's assembly line anymore; it's gearing up to be a top-tier innovation hub. On the surface, might seem like another geopolitical spiel, but dig a little and you'll find it's a serious shake-up for global markets. We're talking about more than just products rolling out of...
Continue Reading
A New Legend in the Making Who would've thought we'd see the day when an SRT badge graced a Jeep Wrangler with such audacity? This ain't your typical Wrangler—they’ve slapped a bit of that CJ-8 throwback swagger, and given it the full-on SRT treatment. It's a mad machine, barreling into the future with one foot firmly planted in its legendary past. You ask any...
Continue Reading
Florida Properties: The Buried Risk in Flood Zones If you’re dreaming of palm trees and sandy beaches, don't let flood zones turn that dream into a nightmare. It’s not all sunshine and rainbows when it comes to buying real estate in Florida, as it turns out—flood zones are lurking, and the devil's in the details. Understanding FEMA Flood Maps First off, these FEMA...
Continue Reading
Navigating New Waters in 2027 ACA Open Enrollment If you're one of those folks who likes to wait until the last minute, the ACA's got a wake-up call for you this year. The 2027 open enrollment period started on November 1, 2026, with some pretty notable changes. The deadline for coverage beginning January 1, 2027, is December 15, so don't take a nap on this one, alright?...
Continue Reading
Blazing Solar Trails in the Digital Landscape Lend an ear, folks, because Beyon's latest leap in the world of renewable energy isn't just another 'look how green we are' maneuver. Announced during Gateway Gulf 2026, this venture is all about serious numbers and even more serious energy chops. Beyon's on course to power a third data center entirely through solar energy,...
Continue Reading
Talk about pulling a rabbit out of the hat! Lazard has just solidified its position in the private capital advisory game with the closure of its acquisition of Campbell Lutyens. They’re now rolling out Lazard CL, merging muscle across different strategies and diversifying those good ol’ revenue streams. It’s a peppy move from Lazard—not just for the cold hard...
Continue Reading
Candy Challenges: Embracing Sweet Joys Responsibly Think you're done with Halloween? Nope. Welcome to the endless candy seasons when every festivity seems like an outlet for sugar overload—with parents caught between letting kids enjoy and guarding their teeth. Now, with Spry's recent push around xylitol, there's an option that might just mean an easier peace between...
Continue Reading
Ever wonder where the cutting edge of military medicine takes shape? On February 16-17, 2027, Washington, DC becomes the epicenter for just that, as the Medical Technology Enterprise Consortium (MTEC) rolls out its 11th Annual Membership Meeting. A gathering of who's who in the world of military medical innovation, this event is like a high-stakes cocktail of science,...
Continue Reading
Breaking Down the TRANSFORM II Trial Innovation never rests, folks, especially when it comes to treating coronary artery disease. Right on cue, the TRANSFORM II trial's results have hit the airwaves, marking a significant milestone with its implant-free MagicTouch Sirolimus-Coated Balloon (SCB) strategy. Getting the Lay of the Land This wasn't just some backyard...
Continue Reading
Top 5 Most Recently Viewed Articles
Key Information for ATYR Pharma Shareholders ATYR Pharma, Inc. has recently faced significant challenges that have caught the attention of its shareholders. Investors who have purchased shares of ATYR during the specified class period are encouraged to stay informed about the ongoing legal developments. Engaging with The Gross Law Firm can provide shareholders with the...
Continue Reading
Zymeworks Keeps Stock Rating Steady After ESMO 2024 Results Zymeworks Inc. (NASDAQ: ZYME) has maintained its stock rating and price target after revealing encouraging results from its recent cancer treatment clinical trials at a significant medical conference. The ratings firm H.C. Wainwright has reiterated a Neutral rating and set a price target of $10.00 per share...
Continue Reading
Introduction to the New ETF A recently introduced exchange-traded fund (ETF), known as the REX Bitcoin Corporate Treasury Convertible Bond ETF (BMAX), is gaining attention for its focus on convertible bonds from companies that have Bitcoin included in their financial strategies. This ETF began trading recently and represents a growing trend in the investment landscape....
Continue Reading
iBio's Strategic Investment Announcement iBio, Inc. (NYSE: IBIO), a pioneer in AI-driven antibody immunotherapies, has made an impactful stride in its mission, announcing the successful closure of a private investment offering totaling over $650,000 from its Board of Directors and corporate officers. This investment is a significant vote of confidence in iBio's strategy...
Continue Reading
Simulmedia Appoints Jonathan Steuer as Chief Scientist Simulmedia, a leader in cross-channel TV and connected TV (CTV) advertising, is thrilled to announce a significant addition to its executive team. Jonathan Steuer, a prominent figure in media research and data science, has been appointed as the Chief Scientist. With a remarkable background as a scientist and...
Continue Reading